TaiRx

TaiRx EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of TaiRx (6580.TWO) as of Oct 18, 2026 is -12.69. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -11.76 — a change of 7.94% (lower).

EV/OCF

-12.69

YoY

7.94%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of TaiRx is 2025 -12.69 . EV/OCF (Enterprise Value to Operating Cash Flow) of TaiRx was 2024 -11.76 . It decreases by 7.94% lower compared to the previous year.

The TaiRx EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-9.40 TWD
Jan 1, 2019
-11.53 TWD
Jan 1, 2020
-11.24 TWD
Jan 1, 2021
-13.85 TWD
Jan 1, 2022
-10.35 TWD
Jan 1, 2023
-8.30 TWD
Jan 1, 2024
-11.76 TWD
Jan 1, 2025
-12.69 TWD
The TaiRx EV/OCF history
YEAREV/OCFYoY
-12.69+7.94%
-11.76+41.70%
-8.30-19.85%
-10.35-25.24%
-13.85+23.15%
-11.24-2.51%
-11.53+22.69%
-9.40-25.84%
-12.68-1.43%
-12.86-29.39%
-18.21-14.97%
-21.42—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

EV/OCF (Enterprise Value to Operating Cash Flow) of TaiRx is -12.69 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of TaiRx changed from -11.76 to -12.69, representing a 7.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) TaiRx since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s TaiRx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TaiRx

All Key Metrics — TaiRx